~Announces another major price reduction on select cancer drugs~
India, Mumbai:
Cipla has always been committed to the treatment and care of cancer patients. As part of this commitment, in 1997, it established the Cipla Palliative Care and Training Centre in Pune, to provide care to advanced stage cancer patients. Today, it is one of the few centres in India offering the best-in class palliative care to cancer patients. The Centre provides free treatment and has cared for over 8,000 patients till date. It has also trained a large number of nurses in advanced palliative care. For more information on the Cipla Palliative Care and Training Centre, please visit www.carebeyondcure.org
In continuation with its commitment to make medicines affordable and accessible, particularly in anti-cancer medication, in May 2012, Cipla announced a dramatic price cut in three major anti-cancer drugs – Sorafenib (SORANIB), Gefitinib (GEFTICIP) and Temozolomide (TEMOSIDE).
Following the overwhelming response on the price cut received from the patients & their families and doctors, Cipla is now announcing another breakthrough price reduction in three additional anticancer drugs – Erlotinib (ERLOCIP), Docetaxel (DOCETAX) and Capecitabine (CAPEGARD). These drugs are for the treatment of Lung and Pancreatic Cancer, Breast Cancer, Head & Neck Cancer, Gastric Cancer, Bladder, Colorectal and Colon Cancers. The revised prices for the selected products are stated below:
| Indication | Molecule | Brand Name |
Current
Price (Rs.) |
Revised Price
(Rs.) |
Reduction
(Rs.) |
| Lung Cancer (Metastatic non-small cell cancer) |
Erlotinib | ERLOCIP 150 30 tablets |
27,000 | 9,900 | 17,100 |
| ERLOCIP 150 10 tablets |
10,000 | 3,700 | 6,300 | ||
| ERLOCIP 100 30 tablets |
18,000 | 6,600 | 11,400 | ||
| Breast Cancer, Lung Cancer (Non-small cell & Small Cell), Head & Neck Cancer, Gastric Cancer, Bladder Cancer |
Docetaxel | DOCETAX 20 mg | 3,300 | 1,650 | 1,650 |
| DOCETAX 80 mg | 10,000 | 5,000 | 5,000 | ||
| DOCETAX 120 mg | 14,000 | 7,000 | 7,000 | ||
| Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Colon Cancer |
Capecitabine | CAPEGARD 500 mg 10 tablets |
1,200 | 600 | 600 |
“Continuing its contribution towards affordable and accessible treatment for patients, Cipla extends the work done in HIV/AIDS and Malaria to now include Cancer, not only in India but globally,” announced Dr. Y.K. Hamied, Chairman and Managing Director, Cipla Limited.
About Cipla
Cipla laid the foundation for the Indian pharmaceutical industry in 1935 , with the vision to make India self-reliant in healthcare. Over the years, Cipla has emerged as one of the most respected names not just in India but worldwide. Its state-of-the-art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. The company has over 34 manufacturing facilities across India, and manufactures 2,000+ products in 65 therapeutic categories.
With a turnover of over US $ 1.4 billion, Cipla serves doctors and patients in over 170 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices.
Visit www.cipla.com
Media Contact:
Antara Mukherjee
Head – Corporate Communications
Mob: (+91) 9967516441
E Mail: antara.mukherjee@cipla.com
Jaisingh Balakrishnan
Corporate Communications
Mob: (+91) 9833836185
E Mail: jaisingh.krishnan@cipla.com
